Hutchmed (China) announced on November 22, 2024, that FRUZAQLA® (Fruquintinib) was launched commercially in Japan by partner Takeda and milestone payments will be received. The drug received production and sales approval from the Japanese Ministry of Health, Labour and Welfare in September 2024, becoming the first oral innovative targeted therapy approved in Japan for the treatment of metastatic colorectal cancer in the past decade. FRUZAQLA® is suitable for late-stage or recurrent colorectal cancer patients who cannot be completely cured, are inoperable, and experience disease progression after chemotherapy. The launch of FRUZAQLA® is based on the results of the FRESCO-2 Phase III study, which were published in The Lancet in June 2023. Takeda holds exclusive global rights to further develop, commercialize, and produce Fruquintinib...Show More

Hutchmed (China) announced on November 22, 2024, that FRUZAQLA® (Fruquintinib) was launched commercially in Japan by partner Takeda and milestone payments will be received. The drug received production and sales approval from the Japanese Ministry of Health, Labour and Welfare in September 2024, becoming the first oral innovative targeted therapy approved in Japan for the treatment of metastatic colorectal cancer in the past decade. FRUZAQLA® is suitable for late-stage or recurrent colorectal cancer patients who cannot be completely cured, are inoperable, and experience disease progression after chemotherapy. The launch of FRUZAQLA® is based on the results of the FRESCO-2 Phase III study, which were published in The Lancet in June 2023. Takeda holds exclusive global rights to further develop, commercialize, and produce Fruquintinib outside mainland China, Hong Kong, and Macao. Fruquintinib is already on the market in the United States, Europe, China, and several other countries and regions, with regulatory applications underway in many others. Dr. Weiguo Su, CEO of Hutchmed (China), stated that the launch of FRUZAQLA® in Japan marks continued progress in their global collaboration with Takeda. Takeda's leading position in metastatic colorectal cancer treatment in Japan will help bring FRUZAQLA®, a differentiated treatment option, to patients.